Functional characterization of polymorphisms in the human TFPI gene

Biochemical and Biophysical Research Communications

Volumn 397, Issue 1, 2010, Pages 106-111

  Skretting, Grethe ^a   Stavik, Benedicte ^a,b   Landvik, Nina E ^c   Myklebust, Christiane F ^a   Iversen, Nina ^a   Zienolddiny, Shan ^c   Sandset, Per Morten ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH   (Norway)

Author keywords

EMSA; Polymorphisms; Reporter gene; TFPI

Indexed keywords

CYTOSINE; DNA; TISSUE FACTOR PATHWAY INHIBITOR; TYROSINE;

ALLELE; ANIMAL CELL; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; CELL STRAIN HEK293; CHO CELL; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBRYO; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE ACTIVITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; VEIN THROMBOSIS;

5' UNTRANSLATED REGIONS; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENES, REPORTER; HUMANS; LIPOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; THROMBOSIS; TRANSCRIPTION, GENETIC;

EID: 77953616244     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.05.078     Document Type: Article

References (29)

1. Bajaj M.S., Kuppuswamy M.N., Saito H., Spitzer S.G., and Bajaj S.P. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc. Natl. Acad. Sci. USA 87 (1990) 8869-8873
2. Girard T.J., Warren L.A., Novotny W.F., Likert K.M., Brown S.G., Miletich J.P., and Broze Jr. G.J. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338 (1989) 518-520
3. Novotny W.F., Brown S.G., Miletich J.P., Rader D.J., and Broze Jr. G.J. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 78 (1991) 387-393
4. Lindahl A.K., Sandset P.M., and Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul. Fibrinolysis 3 (1992) 439-449
5. Huang Z.F., Higuchi D., Lasky N., and Broze Jr. G.J. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 90 (1997) 944-951
6. Sandset P.M., Warn-Cramer B.J., Maki S.L., and Rapaport S.I. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 78 (1991) 1496-1502
7. Sandset P.M., Warn-Cramer B.J., Rao L.V., Maki S.L., and Rapaport S.I. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc. Natl. Acad. Sci. USA 88 (1991) 708-712
8. Holst J., Lindblad B., Bergqvist D., Nordfang O., Ostergaard P.B., Petersen J.L., Nielsen G., and Hedner U. Antithrombotic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis model. Haemostasis 23 (1993) 112-117
9. Kaiser B., and Fareed J. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis. Thromb. Haemost. 76 (1996) 615-620
10. Bajaj M.S., and Bajaj S.P. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb. Haemost. 78 (1997) 471-477
11. Dahm A., Van Hylckama Vlieg A., Bendz B., Rosendaal F., Bertina R.M., and Sandset P.M. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101 (2003) 4387-4392
12. Morange P.E., Renucci J.F., Charles M.A., Aillaud M.F., Giraud F., Grimaux M., and Juhan-Vague I. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thromb. Haemost. 85 (2001) 999-1003
13. Girard T.J., Eddy R., Wesselschmidt R.L., MacPhail L.A., Likert K.M., Byers M.G., Shows T.B., and Broze Jr. G.J. Structure of the human lipoprotein-associated coagulation inhibitor gene. Intron/exon gene organization and localization of the gene to chromosome 2. J. Biol. Chem. 266 (1991) 5036-5041
14. van der Logt C.P., Reitsma P.H., and Bertina R.M. Intron-exon organization of the human gene coding for the lipoprotein-associated coagulation inhibitor: the factor Xa dependent inhibitor of the extrinsic pathway of coagulation. Biochemistry 30 (1991) 1571-1577
15. Petit L., Lesnik P., Dachet C., Hugou I., Moreau M., Chapman J., and Rouis M. The promoter of human tissue factor pathway inhibitor gene: identification of potential regulatory elements. Thromb. Res. 95 (1999) 255-262
16. Bajaj M.S., Tyson D.R., Steer S.A., and Kuppuswamy M.N. Role of GATA motifs in tissue factor pathway inhibitor gene expression in malignant cells. Thromb. Res. 101 (2001) 203-211
17. Liu W., Zhu Z.Q., Wang W., Zu S.Y., and Zhu G.J. Crucial roles of GATA-2 and SP1 in adrenomedullin-affected expression of tissue factor pathway inhibitor in human umbilical vein endothelial cells exposed to lipopolysaccharide. Thromb. Haemost. 97 (2007) 839-846
18. Amini-Nekoo I., and Iles D. Analysis of a T-287C polymorphism in the tissue factor pathway inhibitor gene and identification of a repressor element in the promoter. Thromb. Res. 121 (2008) 813-819
19. Kleesiek K., Schmidt M., Götting C., Brinkmann T., and Prohaska W. A first mutation in the human tissue factor pathway inhibitor gene encoding [P151L]TFPI. Blood 92 (1998) 3976-3977
20. Miyata T., Sakata T., Kumeda K., Uchida K., Tsushima M., Fujimura H., Kawasaki T., and Kato H. C-399T polymorphism in the promoter region of human tissue factor pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen level and does not cause venous thrombosis. Thromb. Haemost. 80 (1998) 345-346
21. Moatti D., Seknadji P., Galand C., Poirier O., Fumeron F., Desprez S., Garbarz M., Dhermy D., Arveiler D., Evans A., Luc G., Ruidavets J.B., Ollivier V., Hakim J., Aumont M.C., and de Prost D. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: impact of the V264M substitution on plasma levels of TFPI. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 862-869
22. Moatti D., Haidar B., Fumeron F., Gauci L., Boudvillain O., Seknadji P., Olliver V., Aumont M.C., and de Prost D. A new T-287C polymorphism in the 5′ regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels. Thromb. Haemost. 84 (2000) 244-249
23. Amini-Nekoo A., Futers T.S., Moia M., Mannucci P.M., Grant P.J., and Ariens R.A. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br. J. Haematol. 113 (2001) 537-543
24. Mues G.I., and Sarode R. Allele frequencies of tissue factor pathway inhibitor polymorphisms in African-American, Hispanic and Caucasian populations. Thromb. Haemost. 88 (2002) 875-877
25. Ameziane N., Seguin C., Borgel D., Fumeron F., Moatti D., Henc-Gelas M., Grandchamp B., Aiach M., Emmerich J., and de Prost D. The -33T→C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations. Thromb. Haemost. 88 (2002) 195-199
26. Sayer M.S., Cole V.J., Adams M.J., Baker R.I., and Staton J.M. Polymorphisms in the tissue factor pathway inhibitor gene are not associated with ischaemic stroke. Blood Coagul. Fibrinolysis 18 (2007) 703-708
27. Moatti D., Meirhaeghe A., Ollivier V., Bauters C., Amouyel P., and de Prost D. Polymorphisms of the tissue factor pathway inhibitor gene and the risk of restenosis after coronary angioplasty. Blood Coagul. Fibrinolysis 12 (2001) 317-323
28. Lincz L.F., Adams M.J., Scorgie F.E., Thom J., Baker R.I., and Seldon M. Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden. Blood Coagul. Fibrinolysis 18 (2007) 559-564
29. Hart K., Haugen A., and Zienolddiny S. Allele-specific induction of IL1B-31T/C promoter polymorphism by lung carcinogens. Mutat. Res. 656 (2008) 14-18